Prolongation of survival of an allograft by inhibiting complement activity

• US 20090028850A1
• Filed: 05/16/2005
• Published: 01/29/2009
• Est. Priority Date: 05/14/2004
• Status: Abandoned Application

• Current Assignee: Alexion Pharmaceuticals Incorporated (Astrazeneca PLC)
• Original Assignee: Alexion Pharmaceuticals Incorporated (Astrazeneca PLC)
• Inventors: Lao, Aili, Wang, Hao, Rother, Russell P.
• Application Number:
  US11/596,382
• Publication Number:
  US 20090028850A1
• Time in Patent Office: Days
• US Class Current: 424/133.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/18 against material from animals or humans

Abstract

Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.

Claims

1. A method to prolong survival of an allograft in a recipient mammal, said method comprising administering to said mammal a) a drug which inhibits complement activity and b) at least one immunosuppressive drug, wherein said drug which inhibits complement activity is administered chronically.

2. The method of claim 1 wherein said mammal is a human.

132. The method of claim 1 wherein i) said recipient is an MHC mismatch to said allograft, ii) said recipient has been presensitized to said allograft, or iii) said recipient is an ABO mismatch to said allograft.

133. The method of claim 1 wherein said drug which inhibits complement activity inhibits the formation of terminal complement or C5a.

134. The method of claim 133 wherein said drug which inhibits formation of terminal complement or C5a is a whole antibody or an antibody fragment.

135. The method of claim 134 wherein said whole antibody or antibody fragment is a human, humanized, chimerized or deimmunized antibody or antibody fragment.

136. The method of claim 134 wherein said whole antibody or antibody fragment inhibits cleavage of complement C5.

137. The method of claim 134 wherein said antibody fragment is selected from the group consisting of an Fab, an F(ab′

)₂, an Fv, and a single-chain antibody.

138. The method claim 1 wherein said drug which inhibits complement activity is administered once every 2 weeks.

139. The method of claim 1 wherein said inhibitor of complement activity is selected from the group consisting of a i) soluble complement receptor, ii) CD59, iii) CD55, iv) CD46, and v) an antibody to C6, C7, C8, or C9.

140. The method of claim 1 wherein said immunosuppressive drug inhibits T-cell activity or B-cell activity.

141. The method of claim 1 wherein said immunosuppressive drug inhibits T-cell activity and B-cell activity.

142. The method of claim 1 wherein said immunosuppressive drug is selected from the group consisting of cyclosporin A, tacrolimus, sirolimus, OKT3, a corticosteroid, daclizumab, basiliximab, azathioprene, mycophenolate mofetil, methotrexate, 6-mercaptopurine, anti-T cell antibodies, cyclophosphamide, leflunamide, brequinar, ATG, ALG, 15-deoxyspergualin, and bredinin.

143. The method of claim 1 wherein more than one immunosuppressive drug is administered.

144. The method of claim 1 wherein said method comprises administering i) a drug which inhibits complement activity and ii) cyclosporin A.

145. The method of claim 144 wherein said drug which inhibits complement activity is an antibody which inhibits cleavage of complement C5.

146. The method of claim 1 wherein said allograft is selected from the group consisting of i) heart, ii) kidney, iii) lung, iv) pancreas, v) liver, vi) vascular tissue, vii) eye, viii) cornea, ix) lens, x) skin, xi) bone marrow, xii) muscle, xiii) connective tissue, xiv) gastrointestinal tissue, xv) nervous tissue, xvi) bone, xvii) stem cells, xviii) islets, xix) cartilage, xx) hepatocytes, and xxi) hematopoietic cells.

147. The method of claim 1 wherein said allograft survives for a time at least 20% longer than would occur if said method were to be performed without said drug which inhibits complement activity.

148. The method of claim 2 wherein said allograft survives for at least six months.

149. The method of claim 1 wherein said drug which inhibits complement activity is administered chronically for at least 14 days.

150. The method of claim 1 wherein at least one immunosuppressive drug is administered chronically for the remaining life-time of said mammal.

151. The method of claim 150 wherein at least cyclosporin A is administered chronically for the remaining life-time of said mammal.

3-131. -131. (canceled)

152. A method to prolong survival of an allograft in a recipient mammal, comprising preparing an allograft from a first allograft accommodated by a first recipient mammal, wherein said first recipient mammal, after receiving said first allograft, has been treated with a drug that inhibits complement activity and at least one immunosuppressive agent.

153. An allograft that has prolonged survival in a recipient mammal, wherein said allograft is prepared from a first recipient mammal and was transplanted to the first recipient mammal that has been treated with a drug that inhibits complement activity and at least one immunosuppressive agent.

154. A pharmaceutical package comprising a drug that inhibits complement activity and at least one immunosuppressive agent, wherein said drug and said agent are formulated for chronic administration.